Madrigal Pharma (MDGL), Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Program
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform
September 19, 2016 7:30 AM EDT- PEN-866 positioned to begin clinical trials in 2017
- Total potential payments to Madrigal may exceed $249 Million
CONSHOHOCKEN, Pa. and WATERTOWN, Mass., Sept. 19, 2016 (GLOBE NEWSWIRE) --... More